AB - The structural modifications on the B - region of the potent and high affinity vanilloid receptor ( VR1leadligand N-(3-acyloxy-2-benzylpropyl)-

to provide the linkage between chemical & biological aspects of life in light of enzymatic reactions(passive) is designedLIGAND

6 ) TABLE 5 FKBP-12 in vitro binding assayresultsLigand

pharmacological or genetic inhibition of ATR , ATM or Chk1 ( a downstream transducer kinase in the pathway(passive) was prevented byLigand upregulation

The absence of one SpreventsCys ligand

Monoclonal antibodies and anti - TGF - β drugscan preventligand

rat bone marrow - derived cellscan contributeto the ligand

Mutations in both genesleadto ligand

This antibody makesto preventligand

DOI : 10.1002 / anie.201205840 Using Ligand - Mapping Simulationsto Designa Ligand

In these cases , the differences between the test compound concentration and the rapamycin control concentration were taken into account using equation 6 below : [ 0000 ] TABLE 5 FKBP-12 in vitro binding assayresultsLigand

control of all of the conformational statescontributeto ligand

e.g. , � C6H5resultingligand : H2(ppb

how one specific multi - targetdesignedligand ( MTDL

For example , bevacizumab targets VEGF - Ato causeligand sequestering

Onartuzumab ... a single - arm antibodypreventsligand

growth necrosis factor - related apoptosiscausingligand ( TRAL

the GUM scope , the largest way use in the cybersecurity(passive) is painted bythe ligand-

An important pH in Pre - NOTCH horizon in the Golgileadsligand

one cell ties to a receptor in the extracellular area of another cell(passive) created byA ligand

of one pyridine unit and two n - butyl - substituted pyrazoles ( pyrz(passive) is composedThe ligand

Binding ability of the adsorbed ligate ( Monoclonal antibody ) to the radiolabelledligand ( chg

intermolecular H - bonding effects as well as steric and electronic factorsinfluencethe ligand

Ramucirumab , a human IgG1 monoclonal antibody directed to the ectodomain of VEGFR-2preventsligand

one - bead - one - compound combinatorial technology as a potent and specific EPC / EC targeting ligand(passive) discovered byligand LXW7

to target many different tumor proteins , such as the folate receptor , which is present on about one - third of human cancers , and prostate - specific membrane antigen , which is present in prostate cancer tumors(passive) can be designedThe ligand

of two parts , one carrying the activity ( agonist or antagonist ) at the different subtypes of OR , the “ message ” and one part , the “ address , ” conveying selectivity toward a given OR ( Portoghese et al . , 1990(passive) is composedthe ligand

Cells were first incubated with a mixture of metabolic inhibitors ( 50 mmol / L 2-deoxy - D - glucose , 15 mmol / L NaN3 , and 1 mg / mL BSA in PBSto preventligand internalization

to bind Ln(III(passive) has been designedThe ligand

EH&Swill leadLigand

Aglaia Oncology Fundcancercervical cancerclinical - stage biopharmaceutical companyfundingGerard PlatenburgISA Pharmaceuticals B.V.persistent viral infectionsproprietary toll - like receptor ( TLRdesignedligand adjuvant

the potential redox noninnocence of hydrazido ligandscould leadto ligand-

on HLA - E(passive) is composedThe ligand

from attaching to the surface via sites important to the interaction under study by having analyte present during immobilization(passive) may be preventedThe ligand

considerable effortdesigningthe ligand

the metal complex(passive) contributed bya ligand

The complex between the ligand and the soluble receptorpreventsthe ligand

the agent being tested(passive) caused bya ligand

The Sixth Editioncausesthe ligand

to fullfill the requirement(passive) was designedOne ligand